UCB sells off production plant and a clutch of older meds in China for $680M

[cafead]

via Restructuring seems to be the name of the game for many large drugmakers these days, and Belgium-based UCB is no exception.

Early Monday, UCB revealed that it’s selling off its mature neurology and allergy business in mainland China to local healthcare asset manager CBC Group and Abu Dhabi-based investment firm Mubadala.

article source